Palomba ML, Jun MP, Lymp J, Nguyen A, et al. Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. Leuk Lymphoma 2021 May 21:1-8. doi: 10.1080/10428194.2021.1910686.
PMID: 34018458